Axinn Successfully Represents Alvogen Before FTC
November 3, 2015
Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen’s approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan’s bid for Perrigo is valued at $25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC’s Mylan press release can be found here.
The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.
Related Services
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Kenina Lee Selected as a Member of Law360’s 2026 Competition Editorial Advisory Board
Awards & Recognitions
Antitrust
Axinn Associates at the Antitrust Spring Meeting: You Get a Deal, You Get a Deal—A Deal in Every Environment
Axinn Viewpoints
Antitrust
Axinn Associates at the Spring Meeting: Trends in Federal Antitrust Enforcement and Policy
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Cartel Enforcement Trends and Developments
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Tech-Related Enforcement
Axinn Viewpoints
Antitrust
Leadership Across the Generations: A Conversation Between Mentor and Mentee
Byline Articles
Antitrust
Ultramarathons Make Me A Better Lawyer
Byline Articles
Antitrust
